Employing DNA Damage Response Inhibitors to Enhance Chemosensitivity of Ovarian Carcinoma Cells

CAI Si-yuan, TANG Zi-zhi, ZENG Ming. et al

Abstract

To assess the sensitisation effects of DDR inhibitors combined with conventional chemotherapeutics agents (cisplatin et al) in a drug-resistant ovarian cancer cell line(OVCAR-8). Methods Inhibitors of DDR regulators with cisplatin were applied to challenge OVCAR-8, and evaluated the DNA damage response (DDR) and cytotoxic effects of different combination of chemicals. Inhibition of proliferation to OVCAR-8 of different drugs was evaluated by MTT assay. The activation of phosphorylation of histone family 2A variant(γH2AX) and p53 binding protein 1 (53BP1) in OVCAR-8 were evaluated by immunofluorescence to observe their ability of recruitment and forming foci at DNA damage site. Results We observed that combined treatment of ataxia-telangiectasia mutated(ATM)/ATM and Rad 3-related(ATR) inhibitor and cisplatin can suppress the activation of damage repair mechanisms and weakened the proliferative activity of OVCAR-8 cells (P<0.01); ATR pathway was suppressed and the signal of γH2AX weakened and cell survival rate significantly reduced when combination therapy of HU and Wortmannin (P<0.05); poly ADP-ribose polymerase (PARP) inhibitor could not enhance chemosensitivity in OVCAR-8 cells when combined with cisplatin (P>0.05). Conclusion We substantiated that appropriate inhibitors of DNA damage response may have a potential to improve the anti-tumor effect of conventional chemotherapy drugs and prevent drug resistances.

 

Keywords: Ovarian cancer, Cisplatin resistance DNA damage response Inhibitors 

 

Full Text:

PDF


References


KARST AM.DRAPKIN R. The new face of ovarian cancer modeling; better prospects for detection and treatment. FI000 Med Rep,2011(3) :22. doi;10. 3410/M3-22.

ARGENTOM, HOFFMAN P, GAUCHEZ AS. Ovarian cancer detection and treatment; current situation and future prospects. Anticancer Res,2008,28(5B):3135-3138.

FERLAY J, SOERJOMATARAM I, DIKSH1T R, et al. Cancer incidence and mortality worldwide; sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5) :E359-E386.

GUBBELS JA. CLAUSSEN N. KAPUR AK, et al. The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res,2010(3) ;8. doi;10. 1186/1757-2215-3-

HAN LY, KIPPS E. KAYE SB. Current treatment and clinical trials in ovarian cancer. Expert Opin Investigl Drugs. 2010,19(4):521-534.

MOSS С, KAYE SB. Ovarian cancer; progress and continuing controversies in management. Eur J Cancer.2002. 38(13):1701-1707.

ROSELL R. LORD RV, TARON M,et al. DNA repair and cisplatin resistance in non-small-cell lungcancer. Lung Cancer. 2002.38( 3): 217-227.

JORDAN P.CARMO-FONSECA M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci,2000;57 (8-9):1229-1235.

BERNSTEIN C. BERNSTEIN H. PAYNE CM.dat. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways; fail-safe protection against carcinogenesis. Mutat Res.2002,511(2): 145-178.

LENGAUER C. KINZLER KW. VOGELSTEIN B. Genetic instabilities in human cancers. Nature, 1998,396(6712):643- 649.

ABRAHAM RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev, 2001, 15 ( 17 ): 2177- 2196.

CRISTIANO BE, CHAN JC, HANNAN KM, et al. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res, 2006,66(24):11718-11725.

HELLEDAY T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol.2011,5(4);387-393.

SNYDER AR, ZHOU J, DENG Z, et al. Therapeutic doses of hydroxyurea cause telomere dysfunction and reduce trf2 binding to telomeres. Cancer Biol Ther, 2009, 8 ( 12): 1136- 1145.

CREGAN SP, DAWSON VL, SLACK RS. Role of AIF in caspase-dependent and caspase independent cell death. Oncogene,2004,23(16):2785-2796.

SCHEEN AJ, LEFEBVRE PJ. Insulin glargine and cancer: a storm in a glass of water? Rev Med Liege,2009 ,64(9) :440- 445.

AUMILLER J. Relationship between diabetology and oncology. Cancer alarm initially without practical consequences. MMW Fortschr Med,2009,151(42); 16.

LOU J, CHU G, ZHOU G, et al. Comparison between two kinds of cigarette smoke condensates ( CSCs ) of the cytogenotoxicity and protein expression in a human B-cell lymphoblastoid cell line using CCK-8 assay, comet assay and protein microarray. Mutat Res,2010,697(1/2) :55-59.

MUMBA ND, MENTEN J, PYANA PP, et al. Stage determination in sleeping sickness; comparison of two cell counting and two parasite detection techniques. Trop Med Int Health.2013,18(6) :778-782.

HUMPEA, BECK C, SCHOCH R. et at. Establishment and optimization of a flow cytometric method for evaluation of viability of CD34+ cells after cryopreser'ation and comparison with trypan blue exclusion staining. Transfusion, 2005,45(7);1208-1213.

MAYLE A, LUO M, JEONG M. et al. Flow cytometry analysis of murine hematopoietic stem cells. Cytometry A, 2013,83(1):27-37.

CHENAL J, PIERRE K. PELLERIN L. Insulin and IGF-1 enhance the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin pathway. Eur J Neurosci,2008,27( 1);53-65.

WAHNER HAE. HALUSKA P. SCHNEIDER PA, et al. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res,2009,69(19);7635-7643.

NAVENOT JM, FUJII N. PEIPER SC. KiSSl metastasis suppressor gene product induces suppression of tyrosine kinase receptor signaling to Akt, tumor necrosis factor family ligand expression, and apoptosis. Mol Pharmacol. 2009, 75 (5):1074-1083.

MIRSHAHI P. RAFII A, VINCENT U et al. Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia, 2009,23 (6); 1039-104 8.

BACK K, BRANNMARK C, STRALFORS P, et al. Differential effects of IGF- I , IGF- П and insulin in human preadipocytes and adipocytes—role of insulin and IGF- I receptors. Mol Cell Endocrinol.2011,339( 1/2); 130-135.

DENLEY A. CARROLL JM. BRIERLEY GV. et al. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol,2007,27( 10):3569-3577.

MENG D, SHI X. JIANG BH. et al. Insulin-like growth factor- I (IGF- I ) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species. Free Radic Biol Med,2007,42( 11); 1651-1660.

SURINYA KH, FORBES BE, OCCHIODORO F. et al. An investigation of the ligand binding properties and negative cooperativity of soluble insulin-like growth factor receptors. J Biol Chem.2008.283(9) ;5355-5363.


Refbacks

  • There are currently no refbacks.